Gary Nachman
Stock Analyst at BMO Capital
(2.35)
# 1,307
Out of 4,667 analysts
100
Total ratings
50%
Success rate
-3.94%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $19.17 | +46.06% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $248.79 | +19.78% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $33.91 | +9.11% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.31 | +364.58% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $17.03 | +117.26% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $19.38 | -1.96% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $287.87 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $27.86 | +7.68% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $4.74 | +47.84% | 1 | Mar 28, 2024 | |
| VERU Veru Inc. | Initiates: Outperform | $3 | $0.63 | +379.77% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $181 → $189 | $167.76 | +12.66% | 13 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $119.24 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $8.41 | -52.44% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $8.73 | +243.64% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $35.40 | +89.27% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $2.67 | +1,098.50% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $13.13 | +6.63% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $5 | $0.37 | +1,262.40% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $4.91 | +714.66% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $17.03 | -41.28% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $24.31 | +23.41% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.49 | +21,389.97% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $8.19 | -2.32% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $44.09 | -52.37% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $3.36 | +316.67% | 2 | Jun 14, 2018 |
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $19.17
Upside: +46.06%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $248.79
Upside: +19.78%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $33.91
Upside: +9.11%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.31
Upside: +364.58%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $17.03
Upside: +117.26%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $19.38
Upside: -1.96%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $287.87
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $27.86
Upside: +7.68%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $4.74
Upside: +47.84%
Veru Inc.
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.63
Upside: +379.77%
Feb 6, 2024
Maintains: Outperform
Price Target: $181 → $189
Current: $167.76
Upside: +12.66%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $119.24
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $8.41
Upside: -52.44%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $8.73
Upside: +243.64%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $35.40
Upside: +89.27%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $2.67
Upside: +1,098.50%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $13.13
Upside: +6.63%
Nov 14, 2022
Maintains: Outperform
Price Target: $6 → $5
Current: $0.37
Upside: +1,262.40%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $4.91
Upside: +714.66%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $17.03
Upside: -41.28%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $24.31
Upside: +23.41%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.49
Upside: +21,389.97%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $8.19
Upside: -2.32%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $44.09
Upside: -52.37%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $3.36
Upside: +316.67%